GRCE — Grace Therapeutics Inc · catalysts, narrative & risks

Company Snapshot

Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage, clinical-phase biopharma company headquartered in Princeton, New Jersey, formerly known as Acasti Pharma Inc. (renamed October 2024) [9][11]. It develops drug-delivery technologies for rare and orphan diseases, with lead candidate GTx-104, an injectable (IV) formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH) [6][8]. As of late October 2026 the stock closed near $1.94 with a market capitalization of roughly $44M [1][8]. Its fiscal year ends March 31 [9][11].